SlideShare une entreprise Scribd logo
1  sur  15
MEASLES
MINA MONTEFRIO
FEVER WARD HEAD NURSE
Measles Virus
1. Paramyxovirus (RNA)
2. One antigenic type
3. Rapidly inactivated by
heat, sunlight, acidic pH,
ether and trypsin
Measles Pathogenesis
1. Respiratory transmission of virus
2. Replication in nasopharynx and regional lymph nodes
3. Primary viremia 2-3 days after exposure
4. Secondary viremia 5-7 days after exposure
Measles Clinical Features
1. Incubation period 10-12 days
2. Prodrome 2-4 days stepwise
increase in fever to 103°F–
105°F
 cough, coryza,
conjunctivitis
 Koplik spots (rash on
mucous membranes)
3. Rash 2-4 days after prodrome,
14 days after exposure
 persists 5-6 days
 begins on face and upper
neck
 maculopapular, becomes
confluent
4. Recovery: fades in order of
appearance
Measles Complications
1. Diarrhea 8%
2. Otitis media 7%
3. Pneumonia 6%
4. Encephalitis 0.1%
5. Seizures 0.6-0.7%
6. Death 0.2%
Measles Laboratory Diagnosis
1. Isolation of measles virus from urine, nasopharynx, blood, throat
2. Significant rise in measles IgG by any standard serologic assay
(e.g., EIA, HI)
3. Positive serologic test for measles IgM antibody
Measles Epidemiology
1. Reservoir human
2. Transmission respiratory Airborne
3. Temporal pattern peak in late winter–spring
4. Communicability 4 days before to 4 days after rash onset
MMR Vaccine
1. First dose of MMR at 12-15 months
2. 12 months is the minimum age
3. Second dose of MMR at 4-6 years
4. Second dose may be given any time at least 4 weeks
after the first dose Intended to produce measles
immunity in persons who failed to respond to the
first dose.
5. May boost antibody titers in some persons
PREVENTION
MMR Vaccine Indication
1. All children 12 months of age and older
2. Susceptible adolescents and adults without documented
evidence of immunity
3. All persons who work within medical facilities should
have evidence of immunity to measles
NOTE:
*** YOU CAN CONSIDERED TO BE IMMUNE TO MEASLES ONLY IF
YOU RECEIVED 2 DOSES OF MEASLES VACCINE.
Vaccine Contraindications and Precautions
1. History of anaphylactic reactions to neomycin
2. History of severe allergic reaction to any component of the vaccine
3. Pregnancy
4. Immunosuppression
5. Moderate or severe acute illness
6. Recent blood product
7. Personal or family (i.e. sibling or parent) with history of seizures of
any etiology.
 A person with measles can spread the virus to others for about eight days,
starting four days before the rash appears and ending when the rash has
been present for four days.
Communicable period.
TREATMENT AND NURSING INTERVENTION
SUPPORTIVE CARE:
1. INTRAVENOUS FLUIDS (IV)
2. Medications to control fever & pain
3. Antibiotic to treat secondary infection from bacteria
4. Vit. A
5. GOOD nursing care: (INCLUDES)
a. Isolation until 5th of rash
b. kept on bed until fever & cough subsides
c. provide dim light, clean eye lid, irrigate affected eye with saline
d. encourage more fluid intake during fever.
e. Increase humidity (for children) of the room to relieve cough
f. Relieve itching of skin (for children) by tepid bath & soothing lotion
g. Immune serum or gamma-globuline may be given to modify illness & reduce
complication
h. Antibacterial therapy given for treatment of complication (e.i. respiratory
infection & gastroenteritis).
Measles

Contenu connexe

Tendances

Tendances (20)

Chicken pox
Chicken poxChicken pox
Chicken pox
 
8 measles
8 measles8 measles
8 measles
 
Rubella
RubellaRubella
Rubella
 
Chicken pox
Chicken poxChicken pox
Chicken pox
 
Dengue
DengueDengue
Dengue
 
Smallpox
SmallpoxSmallpox
Smallpox
 
Cold chain
Cold chainCold chain
Cold chain
 
Smallpox disease
Smallpox diseaseSmallpox disease
Smallpox disease
 
Chicken pox
Chicken poxChicken pox
Chicken pox
 
Mumps presentation s agun
Mumps presentation   s agunMumps presentation   s agun
Mumps presentation s agun
 
Mumps ppt biju
Mumps ppt bijuMumps ppt biju
Mumps ppt biju
 
Chicken pox
Chicken  poxChicken  pox
Chicken pox
 
Rubella
RubellaRubella
Rubella
 
upper respiratory tract infection
upper respiratory tract infectionupper respiratory tract infection
upper respiratory tract infection
 
Measles
MeaslesMeasles
Measles
 
Pertusis or Whooping cough class presentation
Pertusis or  Whooping cough class presentation Pertusis or  Whooping cough class presentation
Pertusis or Whooping cough class presentation
 
Measles
MeaslesMeasles
Measles
 
Whooping cough (pertussis)
Whooping cough (pertussis)Whooping cough (pertussis)
Whooping cough (pertussis)
 
MEASLES
MEASLESMEASLES
MEASLES
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 

En vedette

Measles, mumps and rubella
Measles, mumps and rubellaMeasles, mumps and rubella
Measles, mumps and rubella
LaurenGentner
 
Virus measles
Virus   measlesVirus   measles
Virus measles
gum9wv
 
Measles - Epidemiology and Control
Measles - Epidemiology and ControlMeasles - Epidemiology and Control
Measles - Epidemiology and Control
Rizwan S A
 
Neonatal sepsis
Neonatal sepsisNeonatal sepsis
Neonatal sepsis
7AFH
 

En vedette (20)

Measles
MeaslesMeasles
Measles
 
Measles
MeaslesMeasles
Measles
 
Measles (rubeola)
Measles (rubeola)Measles (rubeola)
Measles (rubeola)
 
Measles
Measles Measles
Measles
 
Mumps
MumpsMumps
Mumps
 
Measles, mumps and rubella
Measles, mumps and rubellaMeasles, mumps and rubella
Measles, mumps and rubella
 
Virus measles
Virus   measlesVirus   measles
Virus measles
 
German measles
German measlesGerman measles
German measles
 
Sunburn
SunburnSunburn
Sunburn
 
GEMC - Measles, Mumps, Rubella - for Nurses
GEMC - Measles, Mumps, Rubella - for NursesGEMC - Measles, Mumps, Rubella - for Nurses
GEMC - Measles, Mumps, Rubella - for Nurses
 
Bfhi
BfhiBfhi
Bfhi
 
Failure To Thrive
Failure To ThriveFailure To Thrive
Failure To Thrive
 
Measles - Epidemiology and Control
Measles - Epidemiology and ControlMeasles - Epidemiology and Control
Measles - Epidemiology and Control
 
Malnutrition
MalnutritionMalnutrition
Malnutrition
 
Failure to thrive
Failure to thriveFailure to thrive
Failure to thrive
 
Failure to thrive
Failure to thriveFailure to thrive
Failure to thrive
 
Disorders of cell growth and differentiation
Disorders of cell growth and differentiationDisorders of cell growth and differentiation
Disorders of cell growth and differentiation
 
Measles
MeaslesMeasles
Measles
 
Neonatal sepsis
Neonatal sepsisNeonatal sepsis
Neonatal sepsis
 
Fluid and electrolyte balance
Fluid and electrolyte balanceFluid and electrolyte balance
Fluid and electrolyte balance
 

Similaire à Measles

Fever and rash by Dr.Uma
Fever and rash by Dr.UmaFever and rash by Dr.Uma
Fever and rash by Dr.Uma
Dr. Rubz
 
Current scenerio of preventive and control measure of
Current scenerio of preventive and control measure ofCurrent scenerio of preventive and control measure of
Current scenerio of preventive and control measure of
Daulal Chouhan
 
11 Measles
11 Measles11 Measles
11 Measles
ghalan
 
epidemiology of common infectious diseases-resp,git,arthropod.pptx
epidemiology of common infectious diseases-resp,git,arthropod.pptxepidemiology of common infectious diseases-resp,git,arthropod.pptx
epidemiology of common infectious diseases-resp,git,arthropod.pptx
sanakhader3
 

Similaire à Measles (20)

MEASLES - THEORY.ppt
MEASLES - THEORY.pptMEASLES - THEORY.ppt
MEASLES - THEORY.ppt
 
Measles Full PSM
Measles Full PSMMeasles Full PSM
Measles Full PSM
 
MMR
MMRMMR
MMR
 
Romantika (measles)
Romantika (measles)Romantika (measles)
Romantika (measles)
 
Measles
MeaslesMeasles
Measles
 
Measles Lecture final yr MBBS 2017
Measles Lecture final yr MBBS 2017Measles Lecture final yr MBBS 2017
Measles Lecture final yr MBBS 2017
 
Common Pediatric Viral Exanthems
Common Pediatric Viral Exanthems Common Pediatric Viral Exanthems
Common Pediatric Viral Exanthems
 
Fever and rash by Dr.Uma
Fever and rash by Dr.UmaFever and rash by Dr.Uma
Fever and rash by Dr.Uma
 
Vaccine3 polio
Vaccine3 polioVaccine3 polio
Vaccine3 polio
 
Current scenerio of preventive and control measure of
Current scenerio of preventive and control measure ofCurrent scenerio of preventive and control measure of
Current scenerio of preventive and control measure of
 
ADULT HEALTH NURAING COMMUNICABLE DISEASE MEASLES.pptx
ADULT HEALTH NURAING COMMUNICABLE DISEASE MEASLES.pptxADULT HEALTH NURAING COMMUNICABLE DISEASE MEASLES.pptx
ADULT HEALTH NURAING COMMUNICABLE DISEASE MEASLES.pptx
 
11 Measles
11 Measles11 Measles
11 Measles
 
Mmr
MmrMmr
Mmr
 
Measles and Rubella
Measles and Rubella Measles and Rubella
Measles and Rubella
 
Measles
Measles Measles
Measles
 
Epidemiology of chickenpox.pptx. ..
Epidemiology of chickenpox.pptx.       ..Epidemiology of chickenpox.pptx.       ..
Epidemiology of chickenpox.pptx. ..
 
Overview of medicine
Overview of medicineOverview of medicine
Overview of medicine
 
Measles ( rubeola ).pptx
Measles  ( rubeola ).pptxMeasles  ( rubeola ).pptx
Measles ( rubeola ).pptx
 
epidemiology of common infectious diseases-resp,git,arthropod.pptx
epidemiology of common infectious diseases-resp,git,arthropod.pptxepidemiology of common infectious diseases-resp,git,arthropod.pptx
epidemiology of common infectious diseases-resp,git,arthropod.pptx
 
3. Measles (Rubella or German measles).ppt
3. Measles (Rubella or German measles).ppt3. Measles (Rubella or German measles).ppt
3. Measles (Rubella or German measles).ppt
 

Plus de MEEQAT HOSPITAL

Plus de MEEQAT HOSPITAL (20)

Updated conscious sedation course.ppt
Updated conscious sedation course.pptUpdated conscious sedation course.ppt
Updated conscious sedation course.ppt
 
fatal asthma.pptx
fatal asthma.pptxfatal asthma.pptx
fatal asthma.pptx
 
Updated algorithm of ER – ICU - In - patients guidelines.pptx
Updated algorithm of ER – ICU -  In - patients guidelines.pptxUpdated algorithm of ER – ICU -  In - patients guidelines.pptx
Updated algorithm of ER – ICU - In - patients guidelines.pptx
 
Blood Bank Lecture .pptx
Blood Bank Lecture .pptxBlood Bank Lecture .pptx
Blood Bank Lecture .pptx
 
Post covid -19 syndrome
Post covid -19 syndromePost covid -19 syndrome
Post covid -19 syndrome
 
Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1Sepsis and septic shock guidelines 2021. part 1
Sepsis and septic shock guidelines 2021. part 1
 
Sepsis hemodynamic update part two
Sepsis hemodynamic update      part twoSepsis hemodynamic update      part two
Sepsis hemodynamic update part two
 
sepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapysepsis SSC 2021 Updates Ventilation and additional therapy
sepsis SSC 2021 Updates Ventilation and additional therapy
 
Sepsis scoring
Sepsis  scoringSepsis  scoring
Sepsis scoring
 
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...Surviving sepsis compaign (adults)Guidelines updates 2021.“Long Term Outcom...
Surviving sepsis compaign (adults) Guidelines updates 2021. “Long Term Outcom...
 
Medication error, nursing responsibility
Medication error, nursing responsibilityMedication error, nursing responsibility
Medication error, nursing responsibility
 
Continuous renal replacement therapy crrt
Continuous renal replacement therapy crrtContinuous renal replacement therapy crrt
Continuous renal replacement therapy crrt
 
Deep venous thrombosis dvt
Deep venous thrombosis dvtDeep venous thrombosis dvt
Deep venous thrombosis dvt
 
Bed sore management
Bed sore managementBed sore management
Bed sore management
 
Chest intubation indications,precautions and management
Chest intubation indications,precautions and managementChest intubation indications,precautions and management
Chest intubation indications,precautions and management
 
Portable ventilator
Portable ventilatorPortable ventilator
Portable ventilator
 
Covid19 corona management -كوفيد19
Covid19 corona management -كوفيد19Covid19 corona management -كوفيد19
Covid19 corona management -كوفيد19
 
Sedation
SedationSedation
Sedation
 
Conscious sedation course
Conscious sedation courseConscious sedation course
Conscious sedation course
 
Electronic medica file
Electronic medica fileElectronic medica file
Electronic medica file
 

Dernier

Dernier (20)

Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Spatium Project Simulation student brief
Spatium Project Simulation student briefSpatium Project Simulation student brief
Spatium Project Simulation student brief
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 

Measles

  • 2.
  • 3. Measles Virus 1. Paramyxovirus (RNA) 2. One antigenic type 3. Rapidly inactivated by heat, sunlight, acidic pH, ether and trypsin
  • 4. Measles Pathogenesis 1. Respiratory transmission of virus 2. Replication in nasopharynx and regional lymph nodes 3. Primary viremia 2-3 days after exposure 4. Secondary viremia 5-7 days after exposure
  • 5. Measles Clinical Features 1. Incubation period 10-12 days 2. Prodrome 2-4 days stepwise increase in fever to 103°F– 105°F  cough, coryza, conjunctivitis  Koplik spots (rash on mucous membranes) 3. Rash 2-4 days after prodrome, 14 days after exposure  persists 5-6 days  begins on face and upper neck  maculopapular, becomes confluent 4. Recovery: fades in order of appearance
  • 6. Measles Complications 1. Diarrhea 8% 2. Otitis media 7% 3. Pneumonia 6% 4. Encephalitis 0.1% 5. Seizures 0.6-0.7% 6. Death 0.2%
  • 7.
  • 8. Measles Laboratory Diagnosis 1. Isolation of measles virus from urine, nasopharynx, blood, throat 2. Significant rise in measles IgG by any standard serologic assay (e.g., EIA, HI) 3. Positive serologic test for measles IgM antibody
  • 9. Measles Epidemiology 1. Reservoir human 2. Transmission respiratory Airborne 3. Temporal pattern peak in late winter–spring 4. Communicability 4 days before to 4 days after rash onset
  • 10. MMR Vaccine 1. First dose of MMR at 12-15 months 2. 12 months is the minimum age 3. Second dose of MMR at 4-6 years 4. Second dose may be given any time at least 4 weeks after the first dose Intended to produce measles immunity in persons who failed to respond to the first dose. 5. May boost antibody titers in some persons PREVENTION
  • 11. MMR Vaccine Indication 1. All children 12 months of age and older 2. Susceptible adolescents and adults without documented evidence of immunity 3. All persons who work within medical facilities should have evidence of immunity to measles NOTE: *** YOU CAN CONSIDERED TO BE IMMUNE TO MEASLES ONLY IF YOU RECEIVED 2 DOSES OF MEASLES VACCINE.
  • 12. Vaccine Contraindications and Precautions 1. History of anaphylactic reactions to neomycin 2. History of severe allergic reaction to any component of the vaccine 3. Pregnancy 4. Immunosuppression 5. Moderate or severe acute illness 6. Recent blood product 7. Personal or family (i.e. sibling or parent) with history of seizures of any etiology.
  • 13.  A person with measles can spread the virus to others for about eight days, starting four days before the rash appears and ending when the rash has been present for four days. Communicable period.
  • 14. TREATMENT AND NURSING INTERVENTION SUPPORTIVE CARE: 1. INTRAVENOUS FLUIDS (IV) 2. Medications to control fever & pain 3. Antibiotic to treat secondary infection from bacteria 4. Vit. A 5. GOOD nursing care: (INCLUDES) a. Isolation until 5th of rash b. kept on bed until fever & cough subsides c. provide dim light, clean eye lid, irrigate affected eye with saline d. encourage more fluid intake during fever. e. Increase humidity (for children) of the room to relieve cough f. Relieve itching of skin (for children) by tepid bath & soothing lotion g. Immune serum or gamma-globuline may be given to modify illness & reduce complication h. Antibacterial therapy given for treatment of complication (e.i. respiratory infection & gastroenteritis).